Kategorier
lobibsweden.com Portaler

Amgen presents New data from PHASE 3 XGEVA (DENOSUMAB) study IN MULTIPLE MYELOMA PATIENTS at THE 16TH INTERNATIONAL MYELOMA

Udgivet1 gang : 18/03/2017 – 01:59

​- Results to be Presented as Late-Breaking Oral Presentation
– Largest International Trial Conducted in Multiple Myeloma
– Study Met Primary Endpoint of Non-Inferiority Versus Zoledronic Acid in Delaying Bone Complications Known as Skeletal-Related Events

Læs mere

Skriv et svar

Din e-mailadresse vil ikke blive publiceret. Krævede felter er markeret med *